HLA-I pMHC Tetramer: From E. coli Expression to T-Cell Detection Reagent | AtaGenix

Why pMHC Tetramers Matter

Identifying and quantifying antigen-specific T cells is central to immunology research, cancer immunotherapy, infectious disease monitoring, and vaccine development. But T-cell receptors (TCRs) bind their cognate peptide-MHC (pMHC) with low affinity — too weak for reliable detection with monomeric reagents. The solution: multimerize biotinylated pMHC monomers onto fluorescently labeled streptavidin to create tetramers, which increase avidity by presenting four pMHC units simultaneously. This transforms a weak interaction into a detectable signal on flow cytometry.

The challenge is that functional pMHC tetramers require every component — HLA heavy chain, β2M, and peptide — to fold correctly together. If any component misfolds, the peptide won't load, and the tetramer won't bind its target T cells. This makes pMHC production one of the most technically demanding applications in recombinant protein expression.

The Challenge

The client needed pMHC tetramers for a specific HLA-I allele loaded with a defined peptide epitope. Commercial tetramer services cover common HLA-A*02:01 alleles, but the client's allele was not available off-the-shelf. They required custom production from scratch: recombinant HLA heavy chain, β2M, optimized refolding with their peptide of interest, biotinylation for streptavidin conjugation, and final tetramer assembly with QC verification — all from a single provider to ensure batch-to-batch consistency.

AtaGenix's Approach

AtaGenix leveraged its MHC-peptide complex expression technology to deliver the complete workflow:

• Expression: HLA-I heavy chain and β2M were separately expressed in E. coli as inclusion bodies — the standard approach for MHC proteins, which require denaturation-refolding to achieve correct conformation with peptide loading.
• Refolding: Solubilized HLA heavy chain, β2M, and the client's target peptide were combined in an optimized refolding buffer. The dilution refolding protocol drives the three components to assemble into a stable ternary pMHC complex (HLA/β2M/peptide). Refolding conditions (redox environment, protein ratios, temperature, dilution rate) were optimized for the specific HLA allele.
• Biotinylation: Refolded pMHC monomers were site-specifically biotinylated using BirA ligase at the C-terminal AviTag, ensuring oriented streptavidin binding without disrupting the peptide-binding groove.
• Tetramer Assembly: Biotinylated pMHC monomers were combined with fluorescence-labeled streptavidin (SA) at optimized molar ratios to form stable tetramers. The assembly was validated by size-exclusion chromatography (SEC) to confirm correct tetramer formation.
• QC: SDS-PAGE confirmed component integrity; SEC-HPLC verified tetramer assembly and absence of free monomer/aggregate; functional utility was confirmed by the client's downstream T-cell staining assays.

Figure 1. pMHC tetramer production workflow. HLA-I heavy chain and β2M were expressed in E. coli, refolded with target peptide to form stable pMHC monomers (HLA/β2M/peptide), biotinylated via BirA, and assembled into tetramers with streptavidin (SA). The resulting tetramers enable high-avidity detection of antigen-specific T cells by flow cytometry.

Results and Impact

The assembled tetramers showed correct molecular weight profile by SEC (tetramer peak with minimal free monomer), and the client confirmed functional staining of antigen-specific CD8⁺ T cells by flow cytometry. By receiving the complete workflow from a single provider — expression, refolding, biotinylation, assembly, and QC — the client avoided the batch-to-batch variability that typically arises when different steps are performed by different labs.

This case study represents an anonymized project outcome. Results may vary depending on HLA allele, peptide sequence, and downstream application. All client information is subject to NDA.